# IDEXX Laboratories Inc. (IDXX) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Medical Devices & Supplies. Price $672.04, market value $52.9 billion.

## Valuation
- **P/E (trailing): 45.3×** (5-yr avg 54.6×, 3-yr avg 48.5×). IDEXX Laboratories Inc. trades at 45.3× trailing earnings, close to its own five-year average of 54.6×. The Healthcare median in the September 2026 study was 28.5×. Forward P/E is 39.9×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 1.77**. A PEG of 1.77 is in the range usually read as fairly priced for its growth.
- **Price / sales: 11.4×**. Each dollar of revenue is priced at 11.4×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 28.3×**. The shares trade at 28.3× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **EV / EBITDA: 32.0×**. Enterprise value is 32.0× operating earnings before depreciation, the multiple that ignores how the company is financed; above 20× is demanding.
- **Free-cash-flow yield: 2.5%** (5-yr avg 1.6%). Free cash flow equals 2.5% of the market value, above its five-year average of 1.6%, so the shares are cheaper on cash than they have usually been.
- **Earnings yield: 2.2%**. The inverse of the P/E: 2.2% of the price is earned each year.

## Profitability
- **Gross margin: 62.7%**. IDEXX Laboratories Inc. keeps 62.7% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: 32.3%**. 32.3% of revenue is left after running the business, an exceptional level.
- **Net margin: 24.6%**. 24.6% of each dollar of sales reaches the bottom line.
- **Return on equity: 66.0%**. A 66.0% return on equity is extremely high; check whether buybacks or debt have shrunk the equity base, which flatters the ratio.
- **Return on invested capital: 63.5%**. Return on all capital, debt included, is 63.5%: comfortably above what that capital costs.
- **Return on assets: 35.3%**. Each dollar of assets produces 35.3% of profit.

## Growth
- **Revenue growth (1 yr): 10.4%** (3-yr 8.5%/yr, 5-yr 9.7%/yr). Revenue grew 10.4% over the last year, against 9.7% a year compounded over five years.
- **EPS growth (1 yr): 22.6%** (3-yr 17.7%/yr, 5-yr 14.3%/yr). Earnings per share rose 22.6%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 38.9%/yr**. Free cash flow has compounded at 38.9% a year over three years, keeping pace with earnings: the growth is real cash.

## Financial health
- **Debt to equity: 0.28**. Debt is 0.28 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 0.2×**. It would take 0.2 years of operating earnings to repay net borrowings, within the comfortable range.
- **Current ratio: 1.23** (quick 1.23). Current assets cover the next year's liabilities 1.23 times.
- **Altman Z-score: 21.59**. A Z-score of 21.59 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 8/9**. 8 of 9 fundamental checks pass: strong and improving financials.

## Dividends
- **Dividend: none**. IDEXX Laboratories Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (12 analysts). 12 analysts cover IDEXX Laboratories Inc.; the consensus is buy, with an average price target of $694.42 (+3% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 6.7%** (YTD -0.7%, 3-mo 18.3%). The shares are up 6.7% over twelve months including dividends.
- **From 52-week high: -12.7%** (34.2% above the low). Trading 13% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 77**. An RSI of 77 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.82** (volatility 39%). Beta of 0.82 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=IDXX · Page: https://foliofundamentals.com/stocks/idxx

Not investment advice.